Alliance completes acquisition of Sinclair’s healthcare products business

Alliance Pharma has strengthened its dermatology portfolio with the 132 million pound acquisition of Sinclair’s healthcare products business. The purchase adds 27 products to the company's offering, including scar treatments Kelo-Cote and Flammacerium, the ulcer relief product Aloclair, stretch-mark treatment Kelo-stretch and atopic dermatitis cream Atopiclair. 

According to Alliance, the acquisition will "significantly increase [its] footprint outside of the UK and will provide an enhanced platform for further corporate development."

With over half of the business now based outside of the UK, the company will have a greater ability to compete for international deals. Alliance sees this deal as a significant turning point for its success.

Sinclair meanwhile says the deal has streamlined its own business, creating a "pure-play highly differentiated aesthetics company, operating in a high growth, self-pay market with high gross margin."